Ametek vs Coherent
AME and COHR side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AME and COHR compare
Ametek is the larger company, worth 1.3 times as much as Coherent ($55.3B against $41.2B).
On earnings, Ametek is cheaper: it trades at 35.3× trailing earnings, against 51.0× for Coherent.
Coherent grew revenue faster over the last twelve months (22.5% versus 12.7% for Ametek).
Ametek keeps more of each dollar of sales as profit, with a net margin of 20.0% compared with 11.3% at Coherent.
Ametek pays a dividend yielding 0.55%; Coherent does not pay one.
Ametek scores higher on the StockData Score (18 against 13 for Coherent), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AME | COHR |
|---|---|---|
| Size and price | ||
| Market cap | $55.3B | $41.2B |
| Share price | $241.12 | $210.32 |
| Change, 1 year | 30.9% | 52.3% |
| Change, 5 years | 71.1% | 227% |
| Beta (5Y) | 0.89 | 2.30 |
| Employees | 13K | 51K |
| StockData Score | ||
| Total score | 18 (better) | 13 |
| Valuation score | 1 | 1 |
| Growth score | 3 | 4 (better) |
| Performance score | 5 (better) | 4 |
| Health score | 6 (better) | 4 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 35.3× (better) | 51.0× |
| P/S | 7.0× | 5.8× (better) |
| P/B | 4.9× | 3.8× (better) |
| EV/EBITDA | 23.1× | – |
| P/FCF | 30.3× | – |
| PEG | 4.15 | – |
| FCF yield | 3.3% (better) | −2.5% |
| Fair value | $207.73 | $177.79 |
| Margin of safety | −16.1% (better) | −18.3% |
| Growth | ||
| Revenue growth (TTM) | 12.7% | 22.5% (better) |
| Revenue growth, 5Y average | 10.3% | 18.0% (better) |
| Net income growth (TTM) | 9.6% | 1531% (better) |
| EPS growth (TTM) | 10.1% | – |
| EPS growth, 5Y average | 11.2% | 11.7% (better) |
| Profitability | ||
| Gross margin | 36.4% | 37.5% (better) |
| Operating margin | 25.9% | – |
| Net margin | 20.0% (better) | 11.3% |
| FCF margin | 23.2% (better) | −14.4% |
| Return on equity | 14.6% (better) | 9.7% |
| Return on invested capital | 13.7% | – |
| Financial health | ||
| Debt / equity | 0.18 (better) | 0.30 |
| Net debt / EBITDA | 0.63 | – |
| Interest coverage | 21.1× | – |
| Current ratio | 1.21 | 2.43 (better) |
| Altman Z-score | 8.23 (better) | 4.26 |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Dividend yield | 0.55% | – |
| Payout ratio | 18.9% | – |
| Buyback yield | 0.80% (better) | −4.9% |
| Shareholder yield | 1.4% (better) | −4.9% |
| Ownership | ||
| Held by institutions | 89.7% | 86.8% |
| Held by insiders | 0.37% | 0.48% |
| Insider net buying, 12 months | −$28.5M (better) | −$1.1B |
| Superinvestors holding | 1 | 2 (better) |
| Short interest, % of float | 1.7% | 5.7% |
Go deeper
- AME stock overview
- AME income statement
- AME valuation and score
- COHR stock overview
- COHR income statement
- COHR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.